A meta-analysis of randomized controlled studies on the effects of extended-release niacin in women

The American Journal of Cardiology
Anne C Goldberg

Abstract

The present meta-analysis pooled data from 5 double-blind, placebo-controlled studies in 432 patients with dyslipidemia treated with various doses of extended-release niacin. Data were analyzed for possible gender differences in response to treatment. At all doses, mean decreases in low-density lipoprotein cholesterol were greater in women than in men; differences were significant at doses of 1,000 mg (6.8% vs 0.2%, p = 0.006), 1,500 mg (11.3% vs 5.6%, p = 0.013), 2,000 mg (14.8% vs 6.9%, p = 0.010), and 3,000 mg (28.7% vs 17.7%, p = 0.006). Decreases in triglyceride levels also tended to be greater in women than in men but reached significance only at the 1,500-mg dose (28.6% vs 20.4%, p = 0.040). No similar trends or significant gender differences were noted in levels of lipoprotein(a) and high-density lipoprotein cholesterol. This meta-analysis confirms that women respond as well as men, and possibly slightly better, to treatment with extended-release niacin and that it is a safe and effective treatment option for women with dyslipidemia.

Citations

Jun 10, 2010·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Yunsuk KohDavid L Nichols
Jul 16, 2005·Journal of Periodontology·Rodrigo F NeivaHom-Lay Wang
Jul 16, 2011·Expert Opinion on Pharmacotherapy·Altan Onat
May 20, 2008·Current Medical Research and Opinion·Sachin J Kamal-BahlCharles E Wentworth
Dec 20, 2007·Nursing for Women's Health·Susan J AppelEmily J Jones
Feb 27, 2009·Clinical Therapeutics·Sachin Kamal-BahlBaishali M Ambegaonkar
Dec 15, 2005·Heart, Lung & Circulation·Avni Sali, Luis Vitetta
Feb 21, 2006·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·R AccinniM Gorini
Oct 1, 2005·The American Journal of Medicine·Robert S Rosenson
Jun 7, 2005·Expert Opinion on Pharmacotherapy·Daniel Schneider, Judith Hsia
Nov 1, 2005·Journal of the American College of Cardiology·Vera Bittner
Jun 16, 2017·The Cochrane Database of Systematic Reviews·Stefan SchandelmaierAlain J Nordmann
Apr 25, 2017·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Paul S JellingerMichael Davidson
Apr 24, 2012·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Paul S JellingerUNKNOWN AACE Task Force for Management of Dyslipidemia and Prevention of Atherosclerosis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.